FI4192882T3 - Sle-nefriitin hoito tyypin i inf-reseptorivasta-aine anifrolumabilla - Google Patents

Sle-nefriitin hoito tyypin i inf-reseptorivasta-aine anifrolumabilla Download PDF

Info

Publication number
FI4192882T3
FI4192882T3 FIEP22724712.9T FI22724712T FI4192882T3 FI 4192882 T3 FI4192882 T3 FI 4192882T3 FI 22724712 T FI22724712 T FI 22724712T FI 4192882 T3 FI4192882 T3 FI 4192882T3
Authority
FI
Finland
Prior art keywords
anifrolumab
dose
use according
subject
administered
Prior art date
Application number
FIEP22724712.9T
Other languages
English (en)
Finnish (fi)
Inventor
Catharina Lindholm
Yen Lin Chia
Rajendra Tummala
Lorin Roskos
Joachim Almquist
Tomas Rouse
Teodora Trasieva
Wendy White
Dominic Sinibaldi
Madhu Ramaswamy
Paul Newcombe
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of FI4192882T3 publication Critical patent/FI4192882T3/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142—Pressure infusion, e.g. using pumps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
    • A61M5/178—Syringes
    • A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775—Apolipopeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/104—Lupus erythematosus [SLE]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Rehabilitation Therapy (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
FIEP22724712.9T 2021-04-23 2022-04-22 Sle-nefriitin hoito tyypin i inf-reseptorivasta-aine anifrolumabilla FI4192882T3 (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163178745P 2021-04-23 2021-04-23
US202163221986P 2021-07-15 2021-07-15
US202163270091P 2021-10-21 2021-10-21
PCT/EP2022/060670 WO2022223771A1 (en) 2021-04-23 2022-04-22 Treatment of lupus nephritis with anti-type i inf receptor antibody anifrolumab

Publications (1)

Publication Number Publication Date
FI4192882T3 true FI4192882T3 (fi) 2025-03-26

Family

ID=81750638

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP22724712.9T FI4192882T3 (fi) 2021-04-23 2022-04-22 Sle-nefriitin hoito tyypin i inf-reseptorivasta-aine anifrolumabilla

Country Status (16)

Country Link
US (2) US20250002590A1 (cg-RX-API-DMAC7.html)
EP (2) EP4595996A3 (cg-RX-API-DMAC7.html)
JP (2) JP7746407B2 (cg-RX-API-DMAC7.html)
KR (1) KR20240001704A (cg-RX-API-DMAC7.html)
AU (1) AU2022260544A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023021514A2 (cg-RX-API-DMAC7.html)
CA (1) CA3216395A1 (cg-RX-API-DMAC7.html)
DK (1) DK4192882T3 (cg-RX-API-DMAC7.html)
ES (1) ES3021882T3 (cg-RX-API-DMAC7.html)
FI (1) FI4192882T3 (cg-RX-API-DMAC7.html)
HU (1) HUE070524T2 (cg-RX-API-DMAC7.html)
IL (1) IL307751B2 (cg-RX-API-DMAC7.html)
PL (1) PL4192882T3 (cg-RX-API-DMAC7.html)
PT (1) PT4192882T (cg-RX-API-DMAC7.html)
TW (1) TW202308691A (cg-RX-API-DMAC7.html)
WO (1) WO2022223771A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202300382T1 (it) 2021-04-23 2024-01-10 Astrazeneca Ab Regime di dosaggio anti-ifnar1 per iniezione sottocutanea
CN113278071B (zh) * 2021-05-27 2021-12-21 江苏荃信生物医药股份有限公司 抗人干扰素α受体1单克隆抗体及其应用
GB202402824D0 (en) * 2024-02-28 2024-04-10 Astrazeneca Ab Treatment of chronic kidney disease

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2643237T3 (es) 2004-06-21 2017-11-21 E. R. Squibb & Sons, L.L.C. Anticuerpos del receptor 1 de interferón alfa y sus usos
MX2010008578A (es) 2008-02-08 2010-11-10 Medimmune Llc Anticuerpos anti-receptor 1 de interferon alfa con afinidad reducida al ligando fc.
SMT201700063T1 (it) 2009-09-03 2017-03-08 Medimmune Llc Diagnosi di interferoni di tipo 1
CN105859889B (zh) * 2010-11-17 2020-01-07 中外制药株式会社 具有代替凝血因子viii的功能的功能的多特异性抗原结合分子
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
CN104603152A (zh) 2012-06-13 2015-05-06 米迪缪尼有限公司 针对抗i型干扰素受体(ifnar)抗体的固定剂量方案
SI3769781T1 (sl) 2015-08-19 2023-06-30 Astrazeneca Ab Stabilna formulacija proti-IFNAR1
US11596699B2 (en) * 2016-04-29 2023-03-07 CureVac SE RNA encoding an antibody
CN106243226B (zh) 2016-08-05 2019-02-12 北京智仁美博生物科技有限公司 抗人ifnar1的抗体及其用途
SMT202300382T1 (it) * 2021-04-23 2024-01-10 Astrazeneca Ab Regime di dosaggio anti-ifnar1 per iniezione sottocutanea
CN113278070B (zh) 2021-04-25 2022-06-14 福州迈新生物技术开发有限公司 抗ck17蛋白单克隆抗体及其细胞株、制备方法和应用
CN113527490B (zh) * 2021-07-13 2022-03-01 江苏荃信生物医药股份有限公司 一种抗人ifnar1单克隆抗体浓缩溶液的制备方法
CN113621063A (zh) * 2021-08-02 2021-11-09 江苏荃信生物医药有限公司 降低单克隆抗体生产中宿主细胞蛋白含量的亲和纯化方法

Also Published As

Publication number Publication date
CA3216395A1 (en) 2022-10-27
TW202308691A (zh) 2023-03-01
AU2022260544A1 (en) 2023-11-30
ES3021882T3 (en) 2025-05-27
IL307751B1 (en) 2025-08-01
US20220348669A1 (en) 2022-11-03
AU2022260544A9 (en) 2023-12-07
IL307751B2 (en) 2025-12-01
US20250002590A1 (en) 2025-01-02
BR112023021514A2 (pt) 2023-12-19
EP4192882B1 (en) 2025-02-19
EP4595996A2 (en) 2025-08-06
JP7746407B2 (ja) 2025-09-30
EP4192882A1 (en) 2023-06-14
KR20240001704A (ko) 2024-01-03
HUE070524T2 (hu) 2025-06-28
PL4192882T3 (pl) 2025-04-28
EP4595996A3 (en) 2025-12-03
JP2024518735A (ja) 2024-05-02
WO2022223771A1 (en) 2022-10-27
IL307751A (en) 2023-12-01
JP2026012677A (ja) 2026-01-27
PT4192882T (pt) 2025-05-02
DK4192882T3 (da) 2025-03-10

Similar Documents

Publication Publication Date Title
RU2359697C2 (ru) Введение средств для лечения воспаления
Leshem et al. Successful treatment of pemphigus with biweekly 1-g infusions of rituximab: a retrospective study of 47 patients
Tepper Anti‐calcitonin gene‐related peptide (CGRP) therapies: Update on a previous review after the American Headache Society 60th Scientific Meeting, San Francisco, June 2018
McKeage et al. Basiliximab: a review of its use as induction therapy in renal transplantation
Strianese Efficacy and safety of immunosuppressive agents for thyroid eye disease
US20130039905A1 (en) Diazoxide For Use In The Treatment Or Prevention Of A Central Nervous System (CNS) Autoimmune Demyelinating Disease
JP2022525149A5 (cg-RX-API-DMAC7.html)
CA2266315A1 (en) Method of preventing acute rejection following solid organ transplantation
IL292706A (en) Type i interferon inhibition in systemic lupus erythematosus
IL307751B1 (en) Treatment of lupus nephritis with anti-type i inf receptor antibody anifrolumab
RU2011117293A (ru) Композиция для лечения заболевания
Lanthier et al. Infliximab in the treatment of posterior uveitis in Behçet's disease: long term follow up in four patients
US8906357B2 (en) Treatment of multiple sclerosis with masitinib
KR20230050363A (ko) 질환의 치료에 있어서 btk 저해제의 용도
Broderick Intracavernous pharmacotherapy: treatment for the aging erectile response
JP2005529152A5 (cg-RX-API-DMAC7.html)
Butty et al. Chronic lymphocytic leukemia–associated membranous glomerulopathy: Remission with fludarabine
Tsuchiya et al. Cognitive effects of scopolamine on temporal preparation in male macaque monkeys
AU2020339737B2 (en) Method for the treatment of chronic fatigue syndrome using an inhibitory or cytotoxic agent against plasma cells
US9913846B2 (en) Combination of a PI3 kinase inhibitor with pacitaxel for use in the treatment or prevention of a cancer of the head and neck
Drulović THE ROLE OF NURSE IN MEDICAL CARE OF PATIENTS SUFFERING FROM MULTIPLE SCLEROSIS; Update on the Treatment Options for Multiple Sclerosis
Lake et al. Maintenance immunosuppression after liver transplantation
Hunt Drug management of the cardiac transplant patient
RU2024129928A (ru) Дозировка и схема введения для лечения или предупреждения синдрома гийена-барре с применением антитела к c5 кровалимаба
Ibrahiem et al. Deferasirox versus deferoxiamine for the treatment of transfusional iron overload in patients with β-thalassemia major